ipss-r vs ipss-m for mds
Published 2 years ago • 638 plays • Length 1:39Download video MP4
Download video MP3
Similar videos
-
1:45
evaluating ipss-r and ipss-m in patients with hr-mds enrolled in stimulus-mds1 and stimulus-mds2
-
2:23
benefits, applicability & uses of the ipss-m in mds
-
3:57
validation of the ipss-m risk stratification system in mds
-
3:31
relevance of the ipss-r during sct in patients with mds in the molecular classification era
-
1:14
how the ipss-m score helps personalizing treatment & combination therapies in hr-mds
-
1:29:13
myelodysplastic syndrome
-
1:09:09
understanding your mds risk score
-
55:44
low risk vs high risk mds - what's the difference?
-
3:35
real-world validation of the value of the ipss-m for prognostication in patients with mds
-
54:01
mds prognosis - understanding ipss and ipss-r scores 2018
-
1:22
benefits and drawbacks of the ipss-m
-
1:34
feasibility of the ipss-m in cmml
-
2:01
updates in mds diagnosis and prognosis with the ipss-m: personalized medicine in 2023
-
1:30
the prognostic value of patient-reported outcomes in mds
-
2:07
ipps-m: incorporating genomic data into the ipps criteria for mds
-
1:16
state of the art: mds
-
1:59
topics of interest in mds: the role of maintenance therapy, immune checkpoints & ven-aza in hr-mds
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
16:07
6-molecular prognostic scoring (ipss-m) – how does it improve patient management?
-
4:02
what is the difference between the ipss and the ipss-r?
-
1:04
the current standard of care for mds-related cytopenias and how treatment strategies may evolve